Physiogenex will be exhibiting at booth#51 and presenting a new DIO-NASH mouse study (abstract#258) at the ILC-EASL in London, UK, on June 25th, 2022.

The poster presentation (#SAT110), entitled “Weight loss with semaglutide treatment or time-restricted feeding differentially improves non-alcoholic steatohepatitis in diet-induced obese insulin resistant mice” will be delivered by Dr. François Briand, our Director of Research and Development, on Saturday June the 25th, 9am-6pm.

Come visit our booth #51 in the exhibition area or contact us if you wish to set-up an appointment with Dr. Briand during the ILC-EASL and/or discuss your drug development projects with us.

About us

 Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.